Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
April 25, 2024 10:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
April 24, 2024 03:00 ET
|
Harness Therapeutics
Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
April 22, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
April 19, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting...
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 11, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the American Academy of Neurology
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting
April 11, 2024 07:00 ET
|
Sania Therapeutics
Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on...
AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA
April 03, 2024 12:09 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE SANTÉ CANADA A JUGÉ ADMISSIBLE LA DEMANDE DE RÉEXAMEN DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Paris, 3 avril 2024, 18h AB Science SA...
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
April 03, 2024 12:09 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024,...
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
March 27, 2024 23:43 ET
|
Indegene Inc
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy